Deliver Your News to the World

Evonik commissions second complex for MetAMINO® production in Singapore

On June 18, 2019, and following the scheduled two-year construction period, Evonik officially commissioned its second complex for the production of MetAMINO® (DL-methionine) and strategically important precursors in Singapore.


Essen / Singapore – WEBWIRE
  • Evonik opens second world-scale plant for methionine production for its Asia growth market
  • Repeat investment of more than half a billion euros
  • Evonik’s annual global capacity of DL-methionine now rises to 730,000 metric tons

On June 18, 2019, and following the scheduled two-year construction period, Evonik officially commissioned its second complex for the production of MetAMINO® (DL-methionine) and strategically important precursors in Singapore. “Our methionine complex on Jurong Island, which we commissioned in late 2014 has been a real success story. Now, we want to continue the success story with this second plant,” said Christian Kullmann, chairman of the Executive Board of Evonik, during the opening festivities.

Each plant has an annual production capacity of 150,000 metric tons of DL-methionine elevating Evonik’s annual global capacity to approximately 730,000 metric tons. The new complex has been modeled on the successful existing plant and has been constructed right next to it. “Synergies from the infrastructure that we set up in 2014, the complete backward integration of both plants into the precursor products, and the joint operation of the entire complex will bring about significant structural efficiency gains,” said Kullmann. In total, Evonik has invested more than half a billion euros in the new complex and has created more than 100 additional jobs at the site.

Evonik produces MetAMINO® in world-scale plants in Antwerp (Belgium), Wesseling/Cologne (Germany), Mobile (Alabama, USA), and in Singapore. This global production network ensures the highest supply security for its customers.

As Johann-Caspar Gammelin, chairman of the board of management of Evonik Nutrition & Care GmbH, explained, the demand for the methionine amino acid for animal nutrition in Asia continues to show strong growth. “On the one hand, the growing consumer affluence in Asia supports the increasing demand for animal protein. On the other, producers are increasingly focusing on more sustainable production of meat, eggs, milk, and fish. We are proud that our MetAMINO® plays a key role in supporting these efforts,” says Gammelin.

DL-methionine is an essential amino acid which must be ingested as part of healthy nutrition. When added to poultry and pig feed, the crude protein content in the feed can be reduced, which benefits the animal organisms, and also reduces the impact on the environment. Through its contribution to efficient, healthy and environmentally friendly animal nutrition, the feed additive is an important component in providing a sustainable supply of animal protein for the world’s growing population.

Evonik’s Animal Nutrition business line has over 60 years of experience in the manufacture of essential amino acids and provides customers in more than 100 countries with solutions for efficient and sustainable animal nutrition. By extending its product range to include additional innovative and sustainable solutions in feed additives, and digital software concepts for efficient farm management, Evonik is making a substantial contribution to a holistic approach to healthy animal nutrition and sustainable animal husbandry, while creating added value for its customers.

The scientifically proven products and services offered by Evonik in the animal nutrition sector play a key role worldwide in the manufacture of healthy and affordable foods, while preserving natural resources and help to reduce the industry’s ecological footprint. “Sciencing the global food challenge” – that’s the Evonik Animal Nutrition commitment.

ABOUT EVONIK

Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-oriented innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world. In fiscal 2018, the enterprise with more than 32,000 employees generated sales of €13.3 billion and an operating profit (adjusted EBITDA) of €2.15 billion from continuing operations.

ABOUT NUTRITION & CARE

The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 8,200 employees, and generated sales of around
€4.6 billion in 2018.

DISCLAIMER

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.


( Press Release Image: https://photos.webwire.com/prmedia/6/242506/242506-1.jpg )


WebWireID242506





This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.